C4 Therapeutics, Inc. (NASDAQ:CCCC) Receives Consensus Rating of “Moderate Buy” from Brokerages

C4 Therapeutics, Inc. (NASDAQ:CCCC) has been assigned an average rating of “Moderate Buy” from the seven ratings firms that are currently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and five have issued a buy recommendation on the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $7.75.

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of C4 Therapeutics in a report on Friday, July 17th.

C4 Therapeutics Price Performance

Shares of C4 Therapeutics stock opened at $4.21 on Thursday. C4 Therapeutics has a 1-year low of $1.69 and a 1-year high of $5.17. The business’s fifty day moving average price is $3.94 and its two-hundred day moving average price is $3.25. The company has a market capitalization of $517.96 million, a P/E ratio of -4.21 and a beta of 2.91.

C4 Therapeutics (NASDAQ:CCCC) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($0.23) by $0.05. The business had revenue of $6.64 million during the quarter, compared to the consensus estimate of $4.00 million. C4 Therapeutics had a negative net margin of 289.44% and a negative return on equity of 45.45%. On average, research analysts expect that C4 Therapeutics will post -0.85 earnings per share for the current fiscal year.

Institutional Trading of C4 Therapeutics

A number of large investors have recently added to or reduced their stakes in CCCC. SummitTX Capital L.P. bought a new position in shares of C4 Therapeutics in the first quarter valued at $28,000. CTC Alternative Strategies Ltd. purchased a new stake in shares of C4 Therapeutics in the first quarter valued at $28,000. Zacks Investment Management purchased a new stake in C4 Therapeutics in the 3rd quarter worth about $29,000. Delta Investment Management LLC acquired a new stake in shares of C4 Therapeutics during the fourth quarter worth approximately $38,000. Finally, Virtu Financial LLC acquired a new stake in shares of C4 Therapeutics during the 4th quarter valued at $39,000. 78.81% of the stock is currently owned by institutional investors.

About C4 Therapeutics

C4 Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted protein degraders. Utilizing its proprietary Controlled Inducible Degradation (CiD) platform, the company seeks to eliminate disease-causing proteins by harnessing the body’s natural protein disposal machinery. This approach aims to address a wide range of oncology and immuno-oncology indications by targeting proteins that have historically been difficult to inhibit with traditional small molecules or antibodies.

The company’s pipeline includes multiple small-molecule degrader candidates advancing through preclinical and clinical stages.